NCT00640978View on ClinicalTrials.gov

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Pancreatic Cancer
Interventions
DRUG

RAD001

30 mg orally weekly for 4 weeks

DRUG

Erlotinib

150 mg by mouth daily for 28 Days

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

OSI Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00640978 - Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter